1. Introduction
Glucocorticoids (GC) are commonly used as anti-inflammatory and immunosuppressive therapy by approximately 1% of the total adult population. Glucocorticoid therapy has also been used in non-autoimmune and non-inflammatory conditions such as acute myocardial infarction, angina, endocarditis as well as in invasive cardiology, coronary interventions and cardiopulmonary- bypass surgery. Despite ample evidence for GC’s role as a natural, physiologic regulator of the immune system, little is known about the molecular events induced by GCs during a stress response. Autophagy is a survival mechanism which is upregulated in response to stress in the cell. It has been described as the cell’s major adaptive strategy in response to a multitude of extracellular stresses, such as nutrient deprivation, mitochondrial damage, endoplasmic reticulum stress or infection. Conserved in all eukaryotes, it is mediated by a unique organelle, the autophagosome, which, under inclusion of cytoplasmic cargo, fuses with lysosomes in order to yield recyclable nutrient metabolites. Basal autophagic activity plays a vital role in maintaining homeostasis during cellular stress. Its malfunction has been implicated with human pathologies such as heart disease, neurological storage disease and cancer.
It is known that GC-triggered autophagy plays a role in cell death during development. However, recent landmark studies also indicate that autophagy operates as a hub, integrating cellular stress, metabolism and glucocorticoid mediated anti-inflammatory action. Importantly, recent lines of evidence suggest that glucocorticoids impact on key signalling components, which control the activity of the autophagic machinery.
In this review we will focus on the connections between these key signaling components and autophagy, describing their central roles as modulators of GC-induced protection during a cellular stress response.
2. Glucocorticoid generation and metabolism
The understanding of the physiological regulation of glucocorticoid activity has considerably improved over the last few decades. The generation of glucocorticoids from cholesterol, which occurs in the zonae fasiculata and reticularis of the adrenal cortex, is tightly regulated by the hypothalamic-pituitary-adrenal (HPA) axis where glucocorticoids regulate its own generation through negative feedback inhibition. Glucocorticoids are produced de novo under this control and are released into the blood as required, with a definite circadian rhythm producing peak concentrations in the early morning [1]. When secreted into the blood, most (90-95%) of glucocorticoids are sequestered to corticosteroid-binding globulin and albumin with the unbound fraction available to interact with their receptors [2]. Metabolic inactivation of glucocorticoids occurs predominantly in the liver, but also in the kidney with inactive metabolites excreted in the urine.
3. Molecular actions of glucocorticoids: Genomic and non-genomic pathways
The classical mode of glucocorticoid-induced gene expression, i.e. the genomic effect involves ligand-dependent activation and release from chaperone proteins (heat shock protein-90 and others), translocation of the receptor-complex to the nucleus where binding of the glucocorticoid receptor to glucocorticoid response element (GRE) in the promoter of the target genes will lead to transcriptional activation of the genes within hours [3, 4]. Activation of glucocorticoid-responsive genes occurs via interaction between the DNA-bound GR and transcriptional co-activator molecules such as CREB-binding protein, which have intrinsic histone acetyltransferase activity and cause acetylation of core histones. This tags histones to recruit chromatin remodeling engines and subsequent association of RNA polymerase II resulting in gene activation [5]. Increasing evidence suggests that glucocorticoids can also cause rapid activation of signaling molecules prior to altering gene expression. These so called non-genomic effects occur within minutes of glucocorticoid exposure and are not affected by inhibiting RNA transcription [5, 6].
Metabolic effects of glucocorticoids represent most of the adverse effects of glucocorticoid therapy and are mainly ascribed to the transcriptional activity of the glucocorticoid receptor, whereas the therapeutically beneficial anti-inflammatory actions are thought to be predominantly caused by the mechanism of transrepression where the activated GR can selectively repress the transcription of specific inflammatory genes without binding to DNA itself but by a number of pleiotropic actions at the promoters of inflammatory genes. Inflammatory genes are regulated by the actions of proinflammatory transcription factors such as nuclear factor-B (NF-B), activator protein -1 (AP-1), and signal transducer and transcription proteins. Activated GR binds to these transcription factors, either directly or indirectly, and recruits co-repressor proteins that blunt the ability of these transcription factors to switch on inflammatory genes [7]. Furthermore, many pro-inflammatory genes are repressed by GC at post-transcriptional level via mRNA destabilization or inhibition of translation, however, this phenomenon cannot be accounted for by transrepression, therefore suggest the existence of an additional anti-inflammatory mechanism of GCs [8].
4. Ischemia/reperfusion-induced stress in the heart
Glucocorticoids play a key role in the response to stress in the heart where it can influence the regulation of blood pressure, inflammation, immune function and cellular energy metabolism [9-10]. These acute effects contribute to an adaptive response in the short term. Although the cardioprotective effects of glucocorticoids in the acute setting of ischemia/reperfusion have been experimentally demonstrated in animals [11-13] and humans [14], the molecular mechanisms still need to be fully elucidated.
Ischemia can be defined as an imbalance between the amount of oxygen, glucose and other substrates needed by the heart [15,16]. This leads to anaerobic metabolism and reduced contractile function. A biochemical imbalance occurs as the maintenance of the metabolism cannot be kept at a steady state due to inadequate coronary flow. A reduction in metabolite clearance also occurs during ischemia and intracellular pH levels drop as the acid by-products of glycolysis accumulate. The severity of ischemic injury depends on the duration of ischemia and subsequent reperfusion [15,16]. If, ischemia is maintained, reversible injury gradually transitions to irreversible injury and a myocardial infarct develops. Reperfusion with its reinforced oxygen and substrate availability is thus a prerequisite for myocardial salvage [16]. However, reperfusion after an ischemic period causes generation of free radicals and is associated with detrimental changes such as enzyme release, arrhythmias and intramyocardial haemorrhage which are known as reperfusion injuries [17]. Cardiomyocytes are highly dependent on a continuous supply of oxygen. During ischemia, cardiomyocyte capacity to generate sufficient ATP and creatine phosphate becomes depleted and multiple adaptive processes occur in response to these hypoxic environments created during ischemia. To reduce oxygen consumption, oxidative phosphorylation is limited and glycolysis is stimulated. This aids in ATP production, even under low oxygen supply [18]. Prolonged ischemia leads to cardiac failure which is characterized by the progressive death of myocytes [19]. Three major morphologies of cell death have been described, viz. apoptosis (type I), cell death associated with autophagy (type II) and necrosis (type III).
5. The basic mechanisms of Autophagy
Autophagy, from greek
The autophagic process can be divided into distinct steps, which include the induction, cargo packaging, vesicle nucleation, vesicle expansion and protein retrieval, docking and fusion and finally vesicle degradation [21]. In brief, the first event is the formation of the isolation membrane of the autophagosome. The Atg1 kinase complex governs these early steps in autophagosome formation. Central to this regulation is the nutrient sensor kinase mTOR (TORC). When mTOR is suppressed due to nutrient starvation, Atg1 kinase activity is triggered and affinity for Atg13 increases [24], which leads to the recruiting of other Atg proteins to initiate autophagosome formation. Cellular sources for this autophagosome formation step have been shown to be Golgi, ER, mitochondria and the plasma membrane [25]. During this process, two strongly interdependent conjugation systems are coordinating the events leading to the formation, elongation and sealing of the isolation membrane [26]. In the first conjugation system, Atg proteins 5, 7, 10 and 12 undergo a multimerization step with Atg16, leading to the formation of an Atg16 homotetramer, which assembles with four Atg12-Atg5 conjugates [27]. In the second conjugation system, the protein Atg8 is Atg4 dependently conjugated with phosphatidylethanolamine (PE) [28]. Reactive oxygen species play a role in controlling this step, as Atg4 oxidization enables autophagosome formation to proceed [29]. Next, two kinase complexes, PI3 kinase and Atg1, participate in the late stages of autophagosome formation. Atg6 (the mammalian orthologue, beclin-1) belongs to the PI3 kinase (PI3-K) class III complex. When Atg1 interacts with Atg13, progression towards a complete autophagosome takes place [27]. Cytoplasmic cargo is now confined. Docking and fusion with a lysosome will allow acidification of the autophagosome lumen, leading to the complete and rapid degradation of cargo into constituent components that are released into cytoplasmic space via permeases (Figure 1).
6. Autophagy as a protective response during stress in the heart
The terminally differentiated nature of cardiomyocytes demands a strong molecular reliance upon a functional autophagic degradation system. In cardiomyocytes autophagy has been described already in the late 1970’s where it was emphasized as an important repair mechanism of sublethal injury [30]. Sybers and coworkers demonstrated the occurrence of myocyte autophagy in a fetal mouse heart that was kept for 1 h in organ culture. In addition they observed that Autophagy was accelerated by oxygen and glucose deprivation, but the hearts function could be restored following resupply of glucose and oxygen. However, when the period of injury lasted for longer than four hours, necrotic cell death was induced [30]. To date, many models have produced clear evidence that upregulation of autophagy promotes cell survival under conditions of metabolic perturbations and energy deprivation [31-33]. In the ischaemic myocardium, autophagy is upregulated rapidly following 20 minutes of coronary artery occlusion, leading to an increased number in autophagosomes [34]. In isolated cardiomyocytes exposed to anoxia-reoxygenation it was shown that inhibition of autophagy leads to an increase in necrotic cell death, which was further increased by additional inhibition of apoptosis [35]. However, enhancing autophagic flux, as indicated by an increased rate of autophagosomal clearance, protects cardiac myocytes against ischaemic injury by reducing apoptosis [31]. Moreover, the homeostatic role of functional basal autophagic activity in the myocardium has been demonstrated by cardiac specific disruption of Atg5, manifesting in impaired contractility, hypertrophy, dilation and sarcomeric disarray [36-37].
7. Detrimental effects of Autophagy in the heart
Literature suggests that autophagy is uniquely controlled during ischemia and reperfusion. A large body of evidence indicates that upregulation of autophagy particularly during the reperfusion phase is detrimental and exacerbates myocyte death. Energy sensing mediated by the 5’-AMP-activated protein kinase (AMPK) appears to be central to this control mechanism. In glucose-deprived cardiac myocytes, autophagy resulting from ischemia has been shown to be accompanied by AMPK activation, and was inhibited by dominant negative AMPK, suggesting an AMPK dependent mechanism [34]. AMPK is rapidly activated during myocardial ischemia, and leads to an increase in glucose uptake and oxidation as well as fatty acid oxidation [38]. Autophagy is enhanced after reperfusion, which is accompanied by an inactivation of AMPK and an increase in beclin-1 [34]. As AMPK switches off ATP-dependent processes, [39] its inactivation at reperfusion may contribute to an unfavorable metabolic environment. Moreover, data indicate that energy sensing mediated by AMPK is also differentially controlled depending on the severity of the ischaemic insult [40]. These reports are strengthened by recent data derived from cultured myoblasts, where a differential induction of cell death was observed, which was dependent on the severity and duration of the ischaemic insult [33]. Only mild ischaemic injury induced autophagy and apoptosis, while severe injury led to primarily necrotic cell death.
8. Autophagy and myocardial metabolism
The total cellular ATP amount in the cardiac myocyte is consumed in less than one minute [41] indicating the very high metabolic demand of the myocardium, and at the same time highlighting the existence of an extremely efficient system of energy conversion. In ischaemic conditions, energy metabolism is disrupted to a level where energy production cannot meet the myocardial energy demand. However, there is a clear role for autophagy in ischemia to influence the cell’s energy profile, indicative to maintain metabolic supply-demand homeostasis [33]. ATP levels decrease rapidly with ischemia and recover rapidly after reperfusion [42]. These dynamics of ATP depletion become highly relevant when considering the molecular overlap between autophagy, apoptosis and necrosis [32; 43-44, Figure 2]. It has been demonstrated that an ATP depletion of >50% is needed in order to change the mode of cell death from apoptotic to necrotic [45].
The above results also stress the significance of the severity and duration of the ischaemic event, to allow a sufficient induction of the autophagic machinery to take place. In fact, a direct relationship between autophagic flux and myocardial function has recently been proposed [50], indicating the strong need to measure autophagic activity accurately. Further characterization of the autophagic flux in clear context with myocardial injury will help to answer questions when autophagy functions as a primarily destructive pathway, manifesting in type II programmed cell death or when autophagy functions in a cytoprotective manner.
9. Autophagy and glucocorticoids-relationship and metabolic response
The multifaceted relationship between autophagy and glucocorticoids is already indicated in embryogenesis. Recent reports not only demonstrate an important metabolic role for autophagy during embryogenesis and postnatal development [51,52], but also indicate a likely molecular link between autophagic programmed cell death and steroids during development [53]. Embryos from the atg5-/- knockout mouse model die perinatally due to energy depletion, leading to a reduced plasma- and tissue amino acid concentration [54]. Moreover, increased apoptosis is displayed in various embryonic tissues derived from such embryos, supporting a role for autophagy in the removal of apoptotic bodies or in delaying the onset of apoptotic cell death [54]. Targeted disruption of beclin 1 in mice also leads to early death in embryogenesis [55]. Many examples of autophagy as a mode of programmed cell death during embryogenesis exist, suggesting that an important role for autophagic cell death in development. It has been shown that autophagic cell death requires the genes ATG7 as well as beclin 1 and can be induced by caspase-8 inhibition [56]. In addition, embryonic fibroblasts from Bax/Bak double knockout mice undergo autophagic cell death, which can be suppressed by inhibitors of autophagy and which is dependent on ATG5. These data suggest a role for Bcl-2 family proteins controlling also non-apoptotic cell death in addition to regulating apoptosis [57]. Especially in lower eukaryotes, the rise in steroid titers can elicit a transcription regulatory hierarchy that results in synchronous autophagic cell death [53]. Such steroid triggered programmed autophagic cell death has been observed in larval salivary gland cells [53] as well as motorneurons [58]. These findings suggest that steroids can play a governing role in very specific scenarios, controlling autophagic activity and the duration of increased flux, which in turn can control the synchronous induction of cell death. It is however not known, whether a robust increase in cortisol release in humans following psychological stress, trauma, sepsis or starvation can elicit similar effects on autophagic activity during embryogenesis. Such studies deserve a great deal of attention.
Although limited data are available, similarities exist between the role of the autophagic pathway as a response mechanism to metabolic perturbations and glucocorticoids in the regulation of metabolic responses. Chronic excessive activation of glucocorticoid receptors leads to major cellular metabolic rearrangements such as insulin resistance, glucose intolerance and dyslipidaemia. Obesity and metabolic syndrome, which are characterized by a nutrient overload, have been associated with a hyperactivation of tissue mTOR, indicating a blunted autophagic response [59]. The systemic glucocorticoid excess is associated with an increase in cardiovascular risk factors [60]. One of the major causes of impact on these risk factors is thought to be the glucocorticoid mediated intravascular volume overload [60]. As the access of glucocorticoids to their receptors is controlled by the isozymes of 11-β-hydroxysteroid dehydrogenase in a tissue specific manner, makes manipulation of this pathway an attractive therapeutic target. By selective isozyme inhibitors, the glucocorticoid activity can be modulated locally, keeping systemic glucocorticoid concentrations within homeostatic range.
Also in the acute setting a relationship exists between glucocorticoid availability and autophagy induction. In the treatment of acute lymphoblastic leukemia, glucocorticoids are used as crucial therapeutic agent, due to their effect on inducing G1 phase cell cycle arrest and apoptosis. Recently it was shown that dexamethasone treatment induces cell death and involves the induction of autophagy before the onset of apoptosis [61]. Moreover, another level of interaction has been demonstrated as the role of autophagy in innate immunity has recently become clear. Both the ATG16L1 risk allele as well as ATG5 are selectively important for the function of the Paneth cell, a specialized epithelial cell in the small intestine [62]. Through genome-wide association screenings it was shown that the autophagic pathway plays a fundamental role in the predisposition to the inflammatory bowel condition Chron’s disease [63]. Taken together, these data indicate the dynamic relationship between glucocorticoid-induced metabolic perturbations, autophagy induction, inflammation and cell death susceptibility. Further investigations are likely to provide new insights into this complex relationship to treat cardiovascular disease more effectively by exploiting the modulation of the autophagic machinery in context with controlling local glucocorticoid activity.
10. The role of the mitogen-activated protein kinases (MAPKs) during ischemia/reperfusion-induced stress in the heart
Great efforts have been made to disentangle the intricate relationship between signalling pathways and the stress response of the heart during ischemia/reperfusion-induced injury. Analysis is complicated due to the fact that several pathways can be activated simultaneously with differential effects. It has become however evident that the MAPKs are major mediators of I/R-induced injury. Recent data pin point the MAPK’s as one of the crossroads between autophagy and glucocorticoid signalling events.
Three major classes of MAPKs (Figure 4), which include the extracellular signal regulated protein kinase (ERK)/p42/44, c-Jun NH2-terminal protein kinase (JNK)/stress activated protein kinase (SAPK) and p38 MAPK families have been identified [64,65]. The ERK pathway has been depicted as a pro-survival pathway and is activated by a variety of mitogens and phorbol esters [66,67]. The JNK and p38 MAPK pathways are regarded as pro-apoptotic pathways and are mainly activated by environmental stress and inflammatory cytokines [67,68].
Studies using chemical inhibitors have led to the conclusion that activation of the p38-MAPK promotes cardiac myocyte death during extended periods of ischemia [69-71]. In a cultured neonatal rat cardiac myocyte model, inhibition of p38-MAPK protects against ischaemic injury by decreasing LDH release [69,70]. In addition, Barancik and co-workers (2000) reported that a specific inhibitor of p38-MAPK, SB203580, protected pig myocardium against ischaemic injury in an
Zechner and co-workers (1998) also reported that overexpression of MKK6 (Figure 4), an upstream activator of p38 MAPK, resulted in protection of cardiac myocytes from apoptosis induced either by anisomycin or MEKK1, an upstream activator of the JNK pathway [74]. In addition, expression of MKK6 elicited a hyperthrophic response, which was enhanced by co-infection of p38 [75]. Therefore, a distinct isoform of p38 MAPK, p38, may participate in mediating cell survival. In contrast, over expression of MKK3 in mouse cardiomyocytes led to apoptosis, which was increased by co-infection of p38 [75]. Therefore differential activation of p38-MAPK isoforms may exert opposing effects: p38 is implicated in cell death, while p38 may mediate myocardial survival.
To determine whether p38 MAPK activation was isoform selective, rat neonatal cardiomyocytes were infected with adenovirus encoding wild-type p38 or p38 [70]. They showed that transfected p38 and p38 were differentially activated during sustained ischemia, with p38 remaining activated but p38 deactivated. Furthermore, cells expressing a dominant negative p38, which prevented ischemia-induced p38 MAPK activation, were resistant to sustained ischaemic injury. Therefore, activation of p38 MAPK isoform is detrimental during ischemia.
11. MAPK inactivation by phosphatases
Dephosphorylation of either the threonine or tyrosine residue within the MAPK activation loop T
In addition to threonine dephosphorylation, these studies also indicated that tyrosine-specific protein phosphatases (PTPs) also contribute to ERK inactivation [76]. Currently, 50 or more PTPs have been characterized [78-80], and although the PC12 cell PTPs were not identified molecularly [76], recent studies in other cell types have identified a possible role for three related PTP gene family members [81-84]. Notwithstanding the importance of these early reports on PP2A and tyrosine-specific PTPs inactivating ERKs, little is known about their general importance in terminating MAPK signaling, of the molecular mechanisms that may control phosphatase catalytic activity, or of their specificity for inactivating different MAPK isoforms.
In contrast to these protein phosphatase classes, there has been significant and rapid progress in our understanding of the role played by a subclass of PTP that possess activity for dephosphorylating both phosphotyrosine and phosphothreonine residues, known as the dual specificity phosphatases (DSPs).
The first mammalian DSP was identified as the mouse immediate early gene 3CH134 or its human orthologue CL100, which is induced rapidly after exposure to growth factors, heat shock, or oxidative stress [85-87]. Recombinant CL100/3CH134 was shown to dephosphorylate threonine and tyrosine residues of ERK, which was paralleled by its inactivation. These studies showed that CL100/3CH134 was specific for dephosphorylation of ERK when compared to a number of other unrelated phosphoproteins [76]. A correlation between 3CH134 levels and ERK inactivation was also found in mammalian cells, leading to its renaming as MAPK phosphatase-1 (MKP-1) [88]. Despite this important early work, the relevance of MKP-1 in ERK inactivation remains to be elucidated. Firstly, ERK activity is apparently normal after deletion of the MKP-1 gene in mice [89]. Secondly, it has also become evident that MKP-1 is at least as effective in inactivating JNK and p38 when compared to the ERKs [90-91]. Thirdly, newly identified members of the DSP gene family appear highly selective for ERK and may represent the true physiological regulators of this MAPK isoform. Since the initial cloning of MKP-1, eight additional mammalian DSP gene family members have been identified and characterized, which include MKP-2, MKP-3, MKP-4, MKP-5, MKP-X, PAC1, M3/6 and B59. These DSPs all appear to be effective in mediating inactivation of MAPKs.
The following model for MAPK inactivation by DSP is suggested (Figure 5). Stimulation by growth factors, cytokines, cellular stresses or some active oncogenes leads to rapid
transcription of one or a subset of DSP genes. Increased DSP transcription may reflect activation of specific MAPK, although alternative pathways are not excluded. After translation of the DSP mRNA into protein, the catalytically inactive DSP translocates to a specific subcellular compartment within either the nucleus or the cytosol. Upon encountering its target MAPK, the DSP binds tightly through its amino terminus, which in turn triggers activation of the phosphatase catalytic domain. If the bound MAPK is already activated, then this will result in its rapid inactivation. Conversely, if the MAPK is not active, then its tight interaction with an active DSP is expected to block any possibility of kinase activation by a subsequent stimulus. MAPKs that fail to bind the DSP within its amino terminus remain active or susceptible to activation after extracellular stimulation. Depending on their cellular localization, these regulatory effects allow for selected inhibition of MAPK activities in specific subcellular compartments. Some DSPs have been shown to possess short half-lives [76], suggesting that in the absence of continued gene transcription and protein synthesis, their rapid turnover limits their duration of action in cells. Overall, tight control of DSP gene induction, combined with their differential binding and catalytic activation by a specific repertoire of MAPKs, provides a sophisticated mechanism for rapid targeted inactivation of selected MAPK activities.
12. MAP kinase phosphatase-1 (MKP-1): A mediator of the beneficial effects of glucocorticoids during ischemia/reperfusion-induced stress in the heart
It is noteworthy that many genes that are positively regulated at post-transcriptional level by p38-MAPK, are negatively regulated at the same level by glucocorticoids. Lasa and co-workers investigated the effects of GCs on the p38-MAPK pathway and have shown that dexamethasone destabilized cyclooxygenase-2 (COX-2) mRNA by inhibiting the function, but not the expression of p38-MAPK [92]. The inhibition of p38-MAPK was then shown to be mediated by MKP-1. We and others have also demonstrated that dexamethasone induces the expression of MKP-1 which potently inactivated p38-MAPK [93-94].
Wu and Bennet (2005) demonstrated that MKP-1 promotes cell survival in fibroblasts through the attenuation of stress responsive MAPK-mediated apoptosis [95]. Upregulation of MKP-1 has also been shown to be associated with cardioprotection by long-chain polyunsaturated fatty acids [93]. It has also been reported that transgenic mice overexpressing MKP-1 were protected, whereas knock-out mice show greater injury after ischemia/reperfusion [96]. The exact mechanism of the beneficial effects of glucocorticoids on the heart during ischemia/reperfusion-induced stress still remain to be established. In view of the significant contribution of apoptosis, necrosis and autophagy during ischemia/reperfusion-induced stress, it is expected that GC-induced cardioprotection to be associated with reduced apoptosis and necrosis. Indeed, Fan and co-workers have demonstrated that dexamethasone, administered intraperitoneally or added directly to the perfusate, significantly improved post-ischemic functional recovery and reduced infarct size compared to untreated controls [94]. These were associated with associated with upregulation of MKP-1 protein expression [94]. Furthermore, it was also shown by us that upregulation of MKP-1 during simulated ischemia/reperfusion is associated with an attenuation of apoptosis in neonatal cardiomyocytes [93].
13. Conclusions
It has been suggested that upregulation of MKP-1 during ischemia/reperfusion-induced stress attenuates myocardial injury [93,94]. MKP-1, found predominantly in the nucleus, is a dual specific phosphatase which dephosphorylates phosphotyrosine and phosphothreonine-containing protein kinases such as the MAPKs. MAPKs are known to be involved in intracellular signalling pathways that regulate gene expression in response to a variety of extracellular signals. MAPKs are activated during ischemia/reperfusion-induced stress in the heart. It was also demonstrated that glucocorticoids act via MKP-1 induction and subsequent p38-MAPK inhibition to induce cardioprotection during ischemia/reperfusion-induced stress [94].
MAPKs have been found to be involved in autophagic, apoptotic and necrotic cell death during stress responses of the heart [97-102]. Autophagy is foremost a survival mechanism which is activated in cells subjected to nutrient or growth factor deprivation. However, when the cellular stress continues, cell death may occur via autophagy, or becomes associated with features of apoptotic or necrotic cell death [103]. Apoptosis is essential for removal of specifically targeted cells, through the process of apoptotic body formation and phagocytosis [104]. Necrosis is a pathological cellular response requiring no ATP. Necrotic cells are morphologically characterized by disrupted membranes, cytoplasm and mitochondrial swelling, disintegration of organelles and complete cell lysis [105]. Cell death following ischemia/reperfusion-induced stress is thought to manifest in morphological features indicative for all three, apoptotic, necrotic and autophagic cell death [106].
MKP-1 has been shown to be involved in the regulation of apoptosis [107] and it was also very recently demonstrated that MKP-1 may lead to autophagy induction in cancer cells [108]. We have recently demonstrated that inhibition of MKP-1 and subsequent increased p38-MAPK phosphorylation during ischemia/reperfusion-induced stress is associated with attenuated autophagy and increased apoptosis and necrosis in the heart (unpublished data). We thus propose the following mechanism of GC-induced protection in the heart: During ischemia/reperfusion-induced stress in the heart, p38 MAPK is activated, GCs sustain/upregulate autophagy via an increase in MKP-1 and subsequent dephosphorylation of p38 MAPK which ultimately protects the heart from apoptosis and necrosis, driven by the effects of autophagy on the metabolic balance sheet of the heart.
References
- 1.
Dallman MF, Strack AM, Akana SF, Bradbury MJ, Hanson ES, Scribner KA 1993 Feast and famine: critical role of glucocorticoids with insulin in daily energy flow Fron Neuroendocrinol14 303 347 - 2.
Hammond GL, Smith CL, Paterson NAM, Sibbald WJ 1990 A role for corticosteroid-globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab71 34 39 - 3.
Buttgereit F. Scheffod A. 2002 Rapid glucocorticoid effects on immune cells. 6 529 534 - 4.
Stellato C. 2004 Port-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc1 255 263 - 5.
Limbourg FP, Liao JK 2003 Nontranscriptional actions of the glucocorticoid receptor. J Mol Med81 168 174 - 6.
Wehling M. 1997 Specific, nongenomic actions of steroid hormones. Annu Rev Physiol59 365 393 - 7.
Ito K. Chung K. F. Adcock I. M. 2006 Update on glucocorticoid action and resistance J Allergy Clin Immunol117 522 543 - 8.
Clark A. R. Dean J. L. Saklatvala J. 2003 Post-transcriptional regulation of gene expression by mitogen-activated protein kinase 38 - 9.
Sapolsky RM, Romero LM, Munck AU 2000 How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev21 55 89 - 10.
Libby P. Maroko P. R. Bloor C. M. Sobel B. E. Braunwald E. 1973 Reduction of experimental myocardial infarct size by corticosteroid administration J Clin Invest52 599 607 - 11.
Valen G. et al. 2000 Glucocorticoid pre-treatment protects cardiac function and induces cardiac heat shock protein 72. Am J Physiol Heart Circ Physiol 279: H836 H843. - 12.
Varga E. et al. 2004 Inhibition of ischemia/reperfusion-induced damage by dexamethasone in isolated working rat hearts: the role of cytochrome c release. Life Sci75 2411 2423 - 13.
Skyschally A. et al. 2004 Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. 109 2337 2342 - 14.
Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE 2003 Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol91 1055 1059 - 15.
Dennis S. C. Gevers W. Opie L. H. 1991 Protons in ischemia: where do they come from: where do they go to? J Mol Cell Cardiol23 1077 1086 - 16.
Zong WX & Thompson SB 2006 Necrotic death as a cell fate. Genes Dev20 1 15 - 17.
Murry CE, Jennings RB & Reimer KA 1986 Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. 74 1124 1136 - 18.
Nishida K. Kyoi S. Yamaguchi O. Sadoshima J. Otsu K. 2009 The role of autophagy in the heart Cell Death Differ16 31 38 - 19.
Olivetti G. Abbi R. Quaini F. Kajstura J. Cheng W. Nitahara J. A. Quaini E. Di Loreto C. CA Beltrami Krajewski. S. Reed J. C. Anversa P. 1997 Apoptosis in the failing human heart. N Engl J Med336 1131 1141 - 20.
De Duve C. Wattiaux R. 1966 Functions of Lysosomes. Ann Rev Physiol28 435 92 - 21.
Mizushima N. Levine B. Cuervo A. M. Klionsky D. J. 2008 Autophagy fights disease through cellular self-digestion 451 7182 1069 75 - 22.
Baba M. Takeshige G. Baba N. Ohsumi Y. 1994 Ultrastructural analysis of the autophagic process in yeast: Detection of autophagosomes and their characterization J Cell Biol6 903 13 - 23.
Dice FJ 2007 Chaperone-Mediated Autophagy. 4 295 9 - 24.
He C. Klionskly D. J. 2009 Regulation mechanisms and signaling pathways in autophagy. Annu Rev Genet43 67 93 - 25.
Cuervo AM 2010 The plasma membrane brings autophagosomes to life Nat.Cell Biol12 735 737 - 26.
Cuervo AM 2004 Autophagy: Many paths to the same end Mol Cell Biochem263 55 72 - 27.
Yorimitsu T. Klionsky D. J. 2005 Autophagy: molecular machinery for self-eating. Cell Death Differ12 1542 1552 - 28.
(Fass E. Amar N. Elazar Z. 2007 ). Identification of essential residues for the c-terminal cleavage of mammalian LC3. Autophagy 3:1:48 EOF 50 EOF . - 29.
Scherz-Shouval R. Shvets E. Elazar Z. 2007 Oxidation as a post-translational modification that regulates autophagy. 4 371 3 - 30.
Sybers H. D. Ingwall J. De Luca M. 1978 Autophagy in cardiac myocytes. Recent Adv Stud Cardiac Struct Metab12 453 463 - 31.
Hamacher-Brady A. Brady N. R. Gottlieb R. A. 2006 Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes. J Biol Chem281 29776 29787 - 32.
Loos B. Engelbrecht A. M. 2009 Cell death: a dynamic response concept 5 5 1 14 - 33.
Loos B. Genade S. Ellis B. Lochner A. Engelbrecht A. M. 2011 At the core of survival: Autophagy delays the onset of both apoptotic and necrotic cell death in a model of ischemic cell injury Exp Cell Res317 1437 1453 - 34.
Matsui Y. Takagi H. Qu X. Abdellativ M. Sakoda H. Asano T. 2007 Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and beclin 1 in mediating autophagy. Circ Res100 914 922 - 35.
Dosenko VE, Nagibin VS, Tumanovska LV and Moibenko AA 2006 Protective effect of autophagy in anoxia-reoxygenation of isolated cardiomyocytes? Autophagy2 4 305 306 - 36.
Yue Z. Jin S. Yang C. Levine A. G. Heintz N. 2003 Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor Proc Natl Acad Sci USA;100 15077 15082 - 37.
Nakai A. Yamaguchi O. Takeda T. Higuchi Y. Hikoso S. Taniike M. 2007 The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med13 619 624 - 38.
Gustafsson ÅB, Gottlieb RA 2009 Autophagy in ischemic heart disease. Circ Res104 150 158 - 39.
Lam A. Lopaschuk G. D. 2007 Anti-anginal effects of partial fatty acid oxidation inhibitors Curr Opin Pharmacol7 179 185 - 40.
Altarejos J. Y. Taniguchi M. AS Clanacham Lopaschuk. G. D. 2005 Myocardial ischemia differentially regulates LKB1 and an alternate 5’-AMP-activated protein kinase kinase. J Biol Chem280 183 190 - 41.
MS Jafri Dudycha. S. J. O’Rourke B. 2001 Cellular energy metabolism: models of cellular respiration. Annu Rev Biomed Eng3 57 81 - 42.
Takagi H. Matsui Y. Sadoshima J. 2007 The role of autophagy in mediating cell survival and death during ischemia and reperfusion in the heart. Antioxid Redox Signal9 1373 1381 - 43.
Grover G. J. Atwal K. S. Sleph P. G. Wang F. L. Monshizadegan H. Monticello T. 2004 Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0 ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity. Am J Physiol Heart Circ Physiol287 1747 1755 - 44.
Kunapuli S. Rosanio S. Schwarz E. R. 2006 How do cardiomyocytes die?” Apoptosis and autophagic cell death in cardiac myocytes. J Card Fail12 381 391 - 45.
Leist M. Single B. Castoldi A. F. Kuhnle S. Nicotera P. 1997 Intracellular adenosine triphosphase (ATP) concentration: A switch in the decision between apoptosis and necrosis. J Exp Med185 1481 6 - 46.
Tatsumi T. Shiraishi J. Keira N. Akashi K. Mano A. Yamanaka S. 2003 Intracellular ATP is required for mitochondrial apoptotic pathways in isolated hypoxic rat cardiac myocytes. Cardiovasc Res59 428 40 - 47.
Singh R. Cuervo A. M. 2011 Autophagy in the cellular energetic balance 13 495 504 - 48.
Mizushima N. Klionsky D. J. 2007 Protein turnover via autophagy: implications for metabolism. Annu Rev Nutr27 19 40 - 49.
Singh R. Kaushik S. Wang Y. Xiang Y. Novak I. Komatsu M. Tanaka K. Cuervo A. M. MJ Czaja 2009 Autophagy regulates lipid metabolism. Nature458 1131 1135 - 50.
Nemchenko A. Chiong M. Turer A. Lavandero S. Hill J. A. 2011 Autophagy as therapeutic target in cardiovascular disease. JMCC51 584 593 - 51.
Juhász G. Csikós G. Sinka R. Erdélyi M. Sass M. 2003 The Drosophila homolog of Aut1 is essential for autophagy and development. FEBS Lett543 154 8 - 52.
Levine B. Klionsky D. J. 2004 Development by self-digestion: molecular mechanisms and biological functions of autophagy. 6 463 477 - 53.
Martin D. N. Balgley B. Dutta S. Chen J. Rudnick P. Cranford J. Kantartzis S. De Voe D. L. Lee C. Baehrecke E. H. 2007 Proteomic analysis of steroid-triggered autophagic programmed cell death during Drosophila development. Cell Death Differ14 916 23 - 54.
Kuma A. Hatano M. Matsui M. Yamamoto A. Nakaya H. Yoshimori T. Ohsumi Y. Tokuhisa T. Mizushima N. 2004 The role of autophagy during the early neonatal starvation period. Nature432 1032 6 - 55.
Yue Z. Jin S. Yang C. Levine A. G. Heintz N. 2003 Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor Proc Natl Acad Sci USA100 15077 15082 - 56.
Yu L. Alva A. Su H. Dutt P. Freundt E. Welsh S. 2004 Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science304 1500 1502 - 57.
Shimizu S. Kanaseki T. Mizushima N. Mizuta T. Arakawa-Kobayashi S. Thompson C. B. Tsujimoto Y. 2004 Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. 6 1221 1228 - 58.
Kinch G. Hoffman K. L. Rodrigues E. M. Zee M. C. Weeks J. C. 2003 Steroid-triggered programmed cell death of a motorneuron is autophagic and involves structural changes in mitochondria. J Comp Neurol17 384 403 - 59.
Khamzina L. Veilleux A. Bergeron S. Marette A. 2005 Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. 146 1473 1481 - 60.
Hadoke P. W. F. Iqbal J. Walker B. R. 2009 Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease Brit J Pharmacol156 689 712 - 61.
Laane E. Tamm K. P. Buentke E. Ito K. Khahariza P. Oscarsson J. Corcoran M. Bkörklund A. C. Hultenby K. Lundin J. Heyman M. Söderhäll S. Mazur J. Porwit A. Pandolfi P. P. Zhivotovsky B. Panaretakis T. Grandér D. 2009 Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ16 1018 1029 - 62.
Cadwell K. Liu J. Y. Brown S. L. Miyoshi H. Loh J. Lennerz J. K. Kishi C. Kc W. Carrero J. A. Hunt S. Stone C. D. Brunt E. M. Xavier R. J. Sleckman B. P. Li E. Mizushima N. Stappenbeck T. S. Virgin H. W. 2008 A key role for autophagy and the autophagy gene Atg16 in mouse and human intestinal Paneth cells. Nature13 456 259 63 - 63.
Deretic V. 2009 Links between autophagy, innate immunity, inflammation and Chron’s disease Dig Dis27 246 251 - 64.
Begum N. Ragolia L. Rienzie J. Mc Carthy M. Duddy N. 1989 Regulation of mitogen-activated protein kinase phosphatase-1 induction by insulin in vascular smooth muscle cells. Evaluation of the role of the nitric oxide signalling pathway and potential defects in hypertension J Biol Chem273 25164 25170 - 65.
Cowan KJ & Storey 2003 Mitogen-activated protein kinases: new signalling pathways functioning in cellular responses to environmental stress J Exp Biol206 1107 1115 - 66.
Marczin N. El -Habashi N. Hoare G. S. Bundy R. E. Yacoub M. 2003 Antioxidants in myocardial ischemia-reperfusion injury: therapeutic potential and basic mechanisms. Arch Biochem Biophys420 222 236 - 67.
Junttila M. R. Li S. P. Wetermarck J. 2008 Phosphatase-mediated crosstalk between MAPK signalling pathways in the regulation of cell surviva l. Faseb J22 954 965 - 68.
Weston CR & Davis RJ 2007 The JNK signal transduction pathway. Curr Opin Cell Biol19 142 149 - 69.
Mackay K. Mochly-Rosen D. 2001 Arachidonic acid protects neonatal rat cardiac myocytes form ischaemic injury through protein kinase C. Cardiovasc Res50 65 74 - 70.
Saurin A. T. Martin J. C. Heads R. J. Foley C. Mockridge J. W. MJ Wright Wang. Y. Marber S. 2000 The role of differential activation of38 mitogen activated protein kinases in preconditioned ventricular myocytes. Faseb J 14: 2237-2246. - 71.
Barancik M. Htun P. Strohm C. Killian S. Schaper W. 2000 Inhibition of the cardiac38 pathway by SB20350 delays ischemic cell death. J Cardiovasc Pharmacol 35: 474-483. - 72.
Ma Kumar X. L. Gao S. Louden F. Lopez C. S. Christopher B. L. Wang T. A. Lee C. Feuerstein J. C. Yue G. Z. T. L. 1999 Inhibition of 38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. - 73.
Yue T. L. Wang C. Gu-L J. Ma Kumar X. L. Lee S. Feuerstein J. C. Thomas G. Z. Maleeff H. Ohlstein B. E. H. 2000 Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused hearts Circ Res86 692 699 - 74.
Zechner D. Craig R. Hanford H. S. Mc Donough P. M. Sabbadini R. A. Glembotski C. C. 1998 MKK6 activates myocardial cell NF-kappaB and inhibits apoptosis in a J Biol Chem 273: 8232-8239.38 mitogen-activated protein kinase-dependent manner. - 75.
Wang X. Martindale J. L. Liu Y. Holbrook N. J. 1998 The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J333 291 300 - 76.
Alessi D. R. Gomez N. Moorhead G. Lewis T. Keyse S. M. Cohen P. 1995 Inactivation of42 MAPK kinase by protein phosphatase 2A and a protein tyrosine phosphatase, but not CL 100, in various cell lines. Curr Biol 5: 283-295. - 77.
Marshall CJ 1995 Specificity of receptor tyrosine kinase signalling: transient versus sustained extracellular signal-regulated kinase activation 80 179 185 - 78.
Neel BG, Tonks NK 1997 Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol9 193 204 - 79.
Hooft van Huijsduijnen. R. 1998 Protein tyrosine phosphatases: counting trees in the forest. 225 1 8 - 80.
Denu JM, Dixon JE 1998 Protein tyrosine phosphatases: mechanisms of catalysis and regulation. Curr Opin Chem Biol2 663 641 - 81.
Wurgler-Murphy S. M. Maeda T. Witten E. A. Saito H. 1997 Regulation of the Saccharomyces cerevisiae HOG1 mitogen activated protein kinase by PTP2 and PTP3 protein tyrosine phosphatases. Mol Cell Biol15 1289 1297 - 82.
Shiozaki K. Russel P. 1995 Cell-cycle control linked to extracellular environment by MAP kinase pathway in fission yeast. 378 739 743 - 83.
Millar J. B. Buck V. Wilkinson M. G. 1995 Pyp1 and Pyp2 PTPases dephosphorylated an osmosensing MAP kinase controlling cell size at division in fission yeast. Genes Dev9 2117 2130 - 84.
Zhan X-L, Deschenes RJ, Guan KL 1997 Differential regulation of FUS3 MAP kinase by tyrosine-specific phosphatases PTP2/PTP3 and dual-specificity phosphatase MSG5 in Saccharomyces cervisiae. Genes Dev11 1690 1702 - 85.
Keyse SM & Emslie EA 1992 Oxidatives stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature359 644 646 - 86.
Charles C. H. Sun H. Lau L. F. Tonks N. K. 1993 MKP-1, an immediate early gene product is a dual specificity phosphatase that dephosphorylates MAP kinases in vivo. 75 3 487 493 - 87.
Noguchi T. Metz R. Chen L. Mattei M. G. Carasco D. Bravo R. 1993 Structure, mapping and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth. Mol Cell Biol13 5195 5205 - 88.
Sun H. Charles C. H. Lau L. F. Tonks N. K. 1993 MKP-1 (3Ch134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. 75 487 493 - 89.
Dorfman K. Carrasco D. Gruda M. Ryan C. Lira S. A. Bravo R. 1996 Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. 13 925 931 - 90.
Chu Y. Solski P. A. Khosravi-Far R. Der Kelly C. J. K. 1996 the mitogen-activated protein kinase phosphatases PAC1, MKP-1 and MKP-2 have unique substrate specificities and reduced activity in vivo towards ERK2 sevenmaker mutation. J B iol Chem271 6497 6501 - 91.
Franklin CC, Kraft AS 1997 Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits J Biol Chem 272: 16917-16923.38 MAPK and stress-activated protein kinase in U937 cells. - 92.
Lasa M. Abraham S. M. Boucheron C. Saklatvala J. Clark A. R. 2002 Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK 38 Mol Cel Biol 22: 7802-7811. - 93.
Engelbrecht-M A. Engelbrecht P. Genade S. Niesler C. Page C. Smuts M. Lochner A. 2005 Long-chain polyunsaturated fatty acids protect the heart against ischemia/reperfusion-induced injury via a MAPK dependent pathway. J Mol Cell Cardiol39 940 954 - 94.
Fan W. J. Genade S. Genis A. Huisamen B. Lochner A. 2009 Dexamethasone-induced cardioprotection: a role for the phosphatase MKP-1? Life Sci84 838 846 - 95.
Wu JJ & Bennett AM 2005 Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAPK and cell survival signalling. J Biol Chem280 16461 16466 - 96.
Kaiser R. A. Bueno O. F. Lips D. J. Doevendans P. A. Jones F. Kimball T. F. JD Molkentin 2004 Targeted inhibition of J Biol Chem 279: 15524-1530.38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. - 97.
Lee T. H. Huang Q. Oikemus S. Shank J. Ventura J. J. Cusson N. Vaillancourt R. R. Su B. Davis R. J. MA Kelliher 2003 The death domain kinase RIP1 is essential for tumor necrosis factor alpha signalling to Mol Cell Biol 23: 8377-8385.38 mitogen-activated protein kinase - 98.
Khan T. A. Bianchi C. Ruel M. Voisine P. Sellke F. W. 2004 Mitogen-activate protein kinase pathways and cardiac surgery. J Thorac Cardiovasc Surg127 806 811 - 99.
Lee T. H. Cusson N. MA Kelliher 2004 The kinase activity of Rip1 is not required for tumor necrosis factor alpha-induced IkappaB kinase or iol Chem 279: 33185-33191.38 MAP kinase activation or for ubiquitination of Rip1 by Traf2. J B - 100.
Codongo P. Meijer A. J. 2005 Autophagy and signalling: Their role in cell survival and cell death. Cell Death Differ12 2 1509 1518 - 101.
Park K. J. Lee S. H. Lee C. H. Jang J. Y. Chung J. Kwon M. H. Kim Y. S. 2009 Upregulation of beclin-1 expression and phosphorylation of Bcl-2 and Biochem Biophys Res Commun 382: 762-729.53 are involved in the JNK-mediated autophagic cell death - 102.
Yang LY, Wu KH, Chiu WT, Wang SH & Shih CM 2009 The cadmium-induced death of mesangial cells results in nephrotoxicity 5 571 572 - 103.
Maiuri M. C. Zalckvar E. Kimchi A. Kroemer G. 2007 Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol8 741 752 - 104.
Peter C. Waibel M. Radu C. G. Yang L. V. Witte O. N. Schulze-Osthoff K. Wesselborg S. Lauber K. 2008 Migration to apoptotic “find-me” signa ls is mediated via the phagocyte receptor G2A. J Biol Chem283 5296 5305 - 105.
Zong WX & Thompson CB 2006 Necrotic death as a cell fate. Genes Dev20 1 15 - 106.
Murphy E. Steenbergen C. 2008 Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury Physiol Rev88 581 609 - 107.
Morisco C. Marrone C. Trimarco V. Crispo S. Monti M. G. Sadoshima J. Trimarco B. 2007 Insulin resistance affects the cytoprotective effect of insulin in cardiomyocytes through an impairment of MAPK phosphatase-1 expression. Cardiovasc Res76 453 464 - 108.
Lu HH, Kao SY, Liu TY, Liu ST, Huang WP, Chang KW, Lin SC 2010 Areca nut extract induced oxidative stress and upregulated hypoxia inducing factor leading to autophagy in oral cancer cells 6 725 737